Kelun-Biotech (06990) announced multiple innovative drug research results at the 2026 European Society for Medical Oncology Congress

Zhitong Finance APP News, Kelun-Biotech (06990) announced that the company has presented multiple clinical research results at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, from October 23 to 27, covering data related to the TROP2-targeting antibody-drug conjugate (ADC) sac-TMT () and the B7-H3-targeting ADC SKB500.